Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intermittent maximal androgen blockade for advanced prostate cancer
ACTRN12608000170325Phase 2Completed
- Sponsor
- Abbott Laboratories
- Start
- May 1999
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of flutamide and leuprolide in prostate cancer (PCa), sponsored by Abbott Laboratories. Primary endpoints: Health-related quality of life, Physiological measures and 4 more. Started May 1999; status: completed.
02
Drugs
flutamideleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on ACTRN12608000170325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12608000170325.